Prognostic significance of cyclooxygenase-2 and DNA topoisomerase IIα expression in oral carcinoma

Head and Neck

Volumn 29, Issue 11, 2007, Pages 1002-1009

  Sakurai, Kazunari ^a   Urade, Masahiro ^a   Noguchi, Kazuma ^a   Hashitani, Susumu ^a   Takaoka, Kazuki ^a   Segawa, Emi ^a   Kishimoto, Hiromitsu ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

COX 2; DNA Topo II ; Oral carcinoma; Overall 5 year survival; Prognostic significance

Indexed keywords

CYCLOOXYGENASE 2; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IIALPHA; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LYMPH NODE METASTASIS; MALE; MOUTH CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; CANCER STAGING; CARCINOMA; CASE CONTROL STUDY; ENZYMOLOGY; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MOUTH TUMOR; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; SURVIVAL RATE;

EID: 39749152903     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20627     Document Type: Article

References (44)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-194.
2. Crowe DL, Hacia JG, Hsieh CL, Sinha UK, Rice H. Molecular pathology of head and neck cancer. Histol Histopathol 2002;17:909-914.
3. Von Dongen GA, Snow GB. Prospectives for future studies in head and neck cancer. Eur J Surg Oncol 1997;23:485-491.
4. Slaughter DP, Southwick SH, Smejkel W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953;9:963-968.
5. Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 1989;17:691-694.
6. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556-2559.
7. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-1280.
8. Parrett ML, Harris R, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 1997;10:503-507.
9. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-3764.
10. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.
11. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-990.
12. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 2000;6:2424-2430.
13. Yoshimura R, Sano H, Masuda C, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89:589-596.
14. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:33157-33160.
15. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
16. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: upregulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 1998;58:1208-1216.
17. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
18. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-3340.
19. Leong J, Hughes-Fulford M, Rakhlin N, Habib A, Maclouf J, Goldyne ME. Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation. Exp Cell Res 1996;224:79-87.
20. Chan G, Boyle J, Yang E, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-994.
21. Sakurai K, Urade M, Noguchi K, et al. Increased expression of cyclooxygenase-2 in human salivary gland tumors. Pathol Int 2001;51:762-769.
22. Peng J, Su C, Chang HC, Chai CY, Hung WC. Overexpression of cyclooxygenase 2 in squamous cell carcinoma of the hypopharynx. Hum Pathol 2002;33:100-104.
23. Sobin LH, Wittekind C. International Union Against Cancer, TNM classification of malignant tumors, 5th ed. New York: Wiley-Liss; 1997.
24. Wood GD, Warnke R. Suppression of endogenous avidin-binding activity in tissue and its relevance to biotin-avidin detection system. J Histochem Cytochem 1981;29:1196-1204.
25. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282:1254-1257.
26. Tomozawa S, Tsuno NH, Sunami E, et al. Cyclooxygenase-2 overexpression correlates with tumor recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83:324-328.
27. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6:4064-4068.
28. Konno H, Baba M, Shoji T, Ohta M, Suzuki S, Nakamura S. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis 2002;19:527-534.
29. Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 in head and neck squamous cell carcinoma. Hum Pathol 2002;33:708-714.
30. Chang BW, Kim DH, Kowalski DP, et al. Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma. Clin Cancer Res 2004;10:1678-1684.
31. Ranelletti FO, Almadori G, Rocca B, et al. Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma. Int J Cancer 2001;95:343-349.
32. Joo YE, Kim HS, Min SW, et al. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Cancer 2002;31:147-154.
33. Peterson S, Haroske G, Hellmich G, Ludwig K, Peterson C, Eicheler W. COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome. Anticancer Res 2002;22:1225-1230.
34. Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002;97:1037-1041.
35. Fux R, SchwabM, Thon K-P, Gleiter CH, Fritz P. Cyclooxygenase-2 in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res 2005;11:4754-4760.
36. Goswami PC, Roti JL, Hunt CR. The cell cycle-coupled expression of topoisomerase II a during S phase is regulated by mRNA stability and is disrupted by heat shock or ionizing radiation. Mol Cell Biol 1996;16:1500-1508.
37. Woessner RD, Mattern MR, Mirabell CK, Johnson RK, Drake FH. Proliferation- and cell cycle-dependent differences in expression of the 170-kilodalton and 180 kilodalton forms of topoisomarase II in NIH-3T3 cells. Cell Growth Differ 1991;2:209-214.
38. Holden JA. DNA topoisomarase II-α as a proliferation marker in endocrine and other neoplasms. Endocrin Pathol 1999;10:97-102.
39. Kuroda J, Urade M, Kishimoto H, et al. Promotion of cell differentiation, and suppression of cell growth and cyclooxygenase-2 expression by differentiation-inducing agents in human oral squamous carcinoma SCC25 cells. Int J Oncol 2005;26:361-367.
40. Takaoka K, Kishimoto H, Segawa E, et al. Elevated cell migration, invasion and tumorigenicity in human KB carcinoma cells transfected with COX-2 c DNA. Int J Oncol 2006;29:1095-1101.
41. Jaeckel EC, Raja S, Tan J, et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor δ with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001;127:1253-1266.
42. Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001;3:53-61.
43. Nishimura N, Urade M, Hashitani S, et al. Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. J Oral Pathol Med 2004;33:614-621.
44. Hashitani S, Urade M, Nishimura N, et al. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol 2003;23:665-672.